Clinical Trial Update: Lazertinib for NSCLC Harboring Activating EGFR Mutations in TKI naïve Patients [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating lazertinib in treatment-naïve non-small cell lung cancer with activating EGFR mutations; the study is currently active but n…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Lazertinib (lazertinib)

Snippet

Sponsor: Se-Hoon Lee | Conditions: NSCLC | Phase 2 | Status: ACTIVE_NOT_RECRUITING